Skip to content

The clinical application of serum soluble FMS-like tyrosine kinase 1 (sFlt-1)/placental growth factor (PIGF) testing in obstetric patients with preeclampsia

The clinical application of serum soluble FMS-like tyrosine kinase 1 (sFlt-1)/placental growth factor (PIGF) testing in obstetric patients with preeclampsia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105650
Enrollment
Unknown
Registered
2025-07-08
Start date
2025-07-10
Completion date
Unknown
Last updated
2025-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational hypertension

Interventions

Low sFlt-1/PIGF ratio group:None
High sFlt-1/PIGF ratio group:None

Sponsors

The Third Affiliated Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Singleton pregnancy; 2.Gestational age from 20 weeks to 41 weeks; 3.Hospitalized patients diagnosed with preeclampsia; 4.Age >= 18 years; 5.Signed informed consent;

Exclusion criteria

Exclusion criteria: 1.Patients with combined significant organ dysfunction; 2.Patients with a high likelihood of loss to follow-up;

Design outcomes

Primary

MeasureTime frame
Proportion developing severe preeclampsia within 1-4 weeks after sFlt-1/PlGF testing;

Secondary

MeasureTime frame
The proportion of pregnancies terminated due to hypertensive disorders;Incidence of adverse maternal and infant outcomes;Usage rates of antihypertensive drugs and corticosteroids;

Countries

China

Contacts

Public ContactHe Fang

The Third Affiliated Hospital of Guangzhou Medical University

hefangjnu@126.com+86 20 8129 2210

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026